High throughput screening of normal and neoplastic tissue samples

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 3, 2010, Pages 253-267

  Erickson, Heidi S ^a,b   Gannot, Gallya ^a   Tangrea, Michael A ^a   Chuaqui, Rodrigo F ^a   Gillespie, John W ^c   Emmert Buck, Michael R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Biomarker discovery; Biomarker validation; High throughput screening; Microdissection; Review; Technologies; Tissue

Indexed keywords

COMPLEMENTARY DNA; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; MITOCHONDRIAL DNA;

BACTERIAL ARTIFICIAL CHROMOSOME; CANCER TISSUE; CAPILLARY ELECTROPHORESIS; CELL CULTURE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; MASS SPECTROMETER; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TISSUE PREPARATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950009634     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710790980540     Document Type: Review

References (142)

1. Ransohoff, D.F. Bias as a threat to the validity of cancer molecularmarker research. Nat. Rev. Cancer, 2005, 5, 142-149.
2. Ransohoff, D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl. Cancer Inst., 2005, 97, 315-319.
3. Baggerly, K.A.; Morris, J.S.; Coombes, K.R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics, 2004, 20, 777-785.
4. Ransohoff, D. F. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer, 2004, 4, 309-314.
5. Baggerly, K.A.; Morris, J.S.; Edmonson, S.R.; Coombes, K.R. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst., 2005, 97, 307-309.
6. Liotta, L.A.; Lowenthal, M.; Mehta, A.; Conrads, T.P.; Veenstra, T.D.; Fishman, D.A.; Petricoin, E.F. Importance of communication between producers and consumers of publicly available experimental data. J. Natl. Cancer Inst., 2005, 97, 310-314.
7. Ransohoff, D.F.; McNaughton C.M.; Fowler, F. J. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am. J. Med., 2002, 113, 663-667.
8. Twombly, R. Identity crisis: finding, defining, and integrating biomarkers still a challenge. J. Natl. Cancer Inst., 2006, 98, 11-12.
9. Ben-Ezra, J.; Johnson, D. A.; Rossi, J.; Cook, N.; Wu, A. Effect of fixation on the amplification of nucleic acids from paraffinembedded material by the polymerase chain reaction. J. Histochem. Cytochem., 1991, 39, 351-354.
10. Klimecki, W.T.; Futscher, B.W.; Dalton, W.S. Effects of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques, 1994, 16, 1021-1023.
11. Ahram, M.; Flaig, M.J.; Gillespie, J.W.; Duray, P.H.; Linehan, W.M.; Ornstein, D.K.; Niu, S.; Zhao, Y.; Petricoin, E.F. 3rd; Emmert-Buck, M.R. Evaluation of ethanol-fixed, paraffinembedded tissues for proteomic applications. Proteomics, 2003, 3, 413-421.
12. Fend, F.; Emmert-Buck, M.R.; Chuaqui, R.; Cole, K.; Lee, J.; Liotta, L.A.; Raffeld, M. Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am. J. Pathol., 1999, 154, 61-66.
13. Gillespie, J.W.; Best, C.J.; Bichsel, V.E.; Cole, K.A.; Greenhut, S.F.; Hewitt, S.M.; Ahram, M.; Gathright, Y.B.; Merino, M.J.; Strausberg, R.L.; Epstein, J.I.; Hamilton, S.R.; Gannot, G.; Baibakova, G.V.; Calvert, V.S.; Flaig, M.J.; Chuaqui, R.F.; Herring, J.C.; Pfeifer, J.; Petricoin, E.F.; Linehan, W.M.; Duray, P.H.; Bova, G.S.; Emmert-Buck, M.R. Evaluation of non-formalin tissue fixation for molecular profiling studies. Am. J. Pathol., 2002, 160, 449-457.
14. Vaught, J.B. Biorepository and biospecimen science: a new focus for CEBP. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1572-1573.
15. Celis, A.; Rasmussen, H.H.; Celis, P.; Basse, B.; Lauridsen, J.B.; Ratz, G.; Hein, B.; Ostergaard, M.; Wolf, H.; Orntoft, T.; Celis, J.E. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis, 1999, 20, 355-361.
16. Ornstein, D.K.; Gillespie, J.W.; Paweletz, C.P.; Duray, P.H.; Herring, J.; Vocke, C.D.; Topalian, S.L.; Bostwick, D.G.; Linehan, W.M.; Petricoin, E.F.3rd; Emmert-Buck, M.R. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242.
17. Esposito, G. Complementary techniques: laser capture microdissection-- increasing specificity of gene expression profiling of cancer specimens. Adv. Exp. Med. Biol., 2007, 593, 54-65.
18. de Bruin, E.C.; van de Pas, S.; Lips, E.H.; van Eijk, R.; van der Zee, M.M.; Lombaerts, M.; van Wezel, T.; Marijnen, C.A.; van Krieken, J.H.; Medema, J.P.; van de Velde, C.J.; Eilers, P.H.; Peltenburg, L.T. Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. BMC Genomics, 2005, 6, 142.
19. Emmert-Buck, M.R.; Bonner, R.F.; Smith, P.D.; Chuaqui, R.F.; Zhuang, Z.; Goldstein, S.R.; Weiss, R.A.; Liotta, L.A. Laser capture microdissection. Science, 1996, 274, 998-1001.
20. Simone, N.L.; Bonner, R.F.; Gillespie, J.W.; Emmert-Buck, M.R.; Liotta, L.A. Tissue microarrays. Trends Genet., 1998, 14, 272-276.
21. Banks, R.E.; Dunn, M.J.; Forbes, M.A.; Stanley, A.; Pappin, D.; Naven, T.; Gough, M.; Harnden, P.; Selby, P.J. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis--preliminary findings. Electrophoresis, 1999, 20, 689-700.
22. Best, C.J.; Emmert-Buck, M.R. Molecular profiling of tissue samples using laser capture microdissection. Expert Rev. Mol. Diagn., 2001, 1, 53-60.
23. Shibata, D.; Hawes, D.; Li, Z.H.; Hernandez, A.M.; Spruck, C.H.; Nichols, P.W. Specific genetic analysis of microscopic tissue after selective ultraviolet radiation fractionation and the polymerase chain reaction. Am. J. Pathol., 1992, 141, 539-543.
24. Rodriguez-Canales, J.; Hanson, J.C.; Tangrea, M.A.; Erickson, H.S.; Albert, P.S.; Wallis, B.S.; Richardson, A.M.; Pinto, P.A.; Linehan, W.M.; Gillespie, J.W.; Merino, M.J.; Libutti, S.K.; Woodson, K.G.; Emmert-Buck, M.R.; Chuaqui, R.F. Identification of a unique epigenetic sub-microenvironment in prostate cancer. J. Pathol., 2007, 211, 410-419.
25. Velculescu, V.E.; Zhang, L.; Vogelstein, B.; Kinzler, K.W. Serial analysis of gene expression. Science, 1995, 270, 484-487.
26. Granjeaud, S.; Bertucci, F.; Jordan, B.R. Expression profiling: DNA arrays in many guises. Bioessays, 1999, 21, 781-790.
27. Russo, G.; Zegar, C.; Giordano, A. Advantages and limitations of microarray technology in human cancer. Oncogene, 2003, 22, 6497-6507.
28. Lockhart, D.J.; Dong, H.; Byrne, M.C.; Follettie, M.T.; Gallo, M.V.; Chee, M.S.; Mittmann, M.; Wang, C.; Kobayashi, M.; Horton, H.; Brown, E.L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol., 1996, 14, 1675-1680.
29. Cheng, Q.; Lau, W.M.; Tay, S.K.; Chew, S.H.; Ho, T.H.; Hui, K.M. Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. Int. J. Cancer., 2002, 98, 419-426.
30. Dhanasekaran, S.M.; Barrette, T.R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412, 822-826.
31. Luo, J.; Duggan, D.J.; Chen, Y.; Sauvageot, J.; Ewing, C.M.; Bittner, M.L.; Trent, J.M.; Isaacs, W.B. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res., 2001, 61, 4683-4688.
32. Luo, J.H.; Yu, Y.P.; Cieply, K.; Lin, F.; Deflavia, P.; Dhir, R.; Finkelstein, S.; Michalopoulos, G.; Becich, M. Gene expression analysis of prostate cancers. Mol. Carcinog., 2002, 33, 25-35.
33. Welsh, J.B.; Sapinoso, L.M.; Su, A.I.; Kern, S.G.; Wang-Rodriguez, J.; Moskaluk, C.A.; Frierson, H.F. Jr; Hampton, G.M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res., 2001, 61, 5974-5978.
34. Singh, D.; Febbo, P.G.; Ross, K.; Jackson, D.G.; Manola, J.; Ladd, C.; Tamayo, P.; Renshaw, A.A.; D'Amico, A.V.; Richie, J.P.; Lander, E.S.; Loda, M.; Kantoff, P.W.; Golub, T.R.; Sellers, W.R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 2002, 1, 203-209.
35. Best, C.J.; Leiva, I.M.; Chuaqui, R.F.; Gillespie, J.W.; Duray, P.H.; Murgai, M.; Zhao, Y.; Simon, R.; Kang, J.J.; Green, J.E.; Bostwick, D.G.; Linehan, W.M.; Emmert-Buck, M.R. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn. Mol. Pathol., 2003, 12, 63-70.
36. Best, C.J.; Gillespie, J.W.; Yi, Y.; Chandramouli, G.V.; Perlmutter, M.A.; Gathright, Y.; Erickson, H.S.; Georgevich, L.; Tangrea, M.A.; Duray, P.H.; Gonzalez, S.; Velasco, A.; Linehan, W.M.; Matusik, R.J.; Price, D.K.; Figg, W.D.; Emmert-Buck, M.R.; Chuaqui, R.F. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin. Cancer Res., 2005, 11, 6823-6834.
37. Mattie, M.D.; Benz, C.C.; Bowers, J.; Sensinger, K.; Wong, L.; Scott, G.K.; Fedele, V.; Ginzinger, D.; Getts, R.; Haqq, C. Optimized high throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer., 2006, 5, 24.
38. Ma, S.; Guan, X.Y.; Beh, P.S.; Wong, K.Y.; Chan, Y.P.; Yuen, H.F.; Vielkind, J.; Chan, K.W. The significance of LMO2 expression in the progression of prostate cancer. J. Pathol., 2007, 211, 278-285.
39. Richardson, A.M.; Woodson, K.; Wang, Y.; Rodriguez-Canales, J.; Erickson, H.S.; Tangrea, M.A.; Novakovic, K.; Gonzalez, S.; Velasco, A.; Kawasaki, E.S.; Emmert-Buck, M.R.; Chuaqui, R.F.; Player, A. Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn. Mol. Pathol., 2007, 16, 189-197.
40. Bull, J.H.; Ellison, G.; Patel, A.; Muir, G.; Walker, M.; Underwood, M.; Khan, F.; Paskins, L. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br. J. Cancer, 2001, 84, 1512-1519.
41. Ashida, S.; Furihata, M.; Katagiri, T.; Tamura, K.; Anazawa, Y.; Yoshioka, H.; Miki, T.; Fujioka, T.; Shuin, T.; Nakamura, Y.; Nakagawa, H. Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin. Cancer Res., 2006, 12, 2767-2773.
42. True, L.; Coleman, I.; Hawley, S.; Huang, C.Y.; Gifford, D.; Coleman, R.; Beer, T.M.; Gelmann, E.; Datta, M.; Mostaghel, E.; Knudsen, B.; Lange, P.; Vessella, R.; Lin, D.; Hood, L.; Nelson, P.S. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc. Natl. Acad. Sci. USA, 2006, 103, 10991-10996.
43. Lipshutz, R.J.; Fodor, S.P.; Gingeras, T.R.; Lockhart, D.J. High density synthetic oligonucleotide arrays. Nat. Genet., 1999, 21, 20-24.
44. Perlmutter, M.A.; Best, C.J.; Gillespie, J.W.; Gathright, Y.; Gonzalez, S.; Velasco, A.; Linehan, W.M.; Emmert-Buck, M.R.; Chuaqui, R.F. Comparison of snap freezing versus ethanol fixation for gene expression profiling of tissue specimens. J. Mol. Diagn., 2004, 6, 371-377.
45. Botstein, D.; Risch, N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat. Genet., 2003, (Suppl 33), 228-237.
46. Bignell, G.R.; Huang, J.; Greshock, J.; Watt, S.; Butler, A.; West, S.; Grigorova, M.; Jones, K.W.; Wei, W.; Stratton, M.R.; Futreal, P.A.; Weber, B.; Shapero, M.H.; Wooster, R. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res., 2004, 14, 287-295.
47. Zhao, X.; Li, C.; Paez, J.G.; Chin, K.; Janne, P.A.; Chen, T.H.; Girard, L.; Minna, J.; Christiani, D.; Leo, C.; Gray, J.W.; Sellers, W.R.; Meyerson, M. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res., 2004, 64, 3060-3071.
48. Matsuzaki, H.; Dong, S.; Loi, H.; Di, X.; Liu, G.; Hubbell, E.; Law, J.; Berntsen, T.; Chadha, M.; Hui, H.; Yang, G.; Kennedy, G.C.; Webster, T.A.; Cawley, S.; Walsh, P.S.; Jones, K.W.; Fodor, S.P.; Mei, R. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat. Methods., 2004, 1, 109-111.
49. Gunderson, K.L.; Kruglyak, S.; Graige, M.S.; Garcia, F.; Kermani, B.G.; Zhao, C.; Che, D.; Dickinson, T.; Wickham, E.; Bierle, J.; Doucet, D.; Milewski, M.; Yang, R.; Siegmund, C.; Haas, J.; Zhou, L.; Oliphant, A.; Fan, J.B.; Barnard, S.; Chee, M.S. Decoding randomly ordered DNA arrays. Genome Res., 2004, 14, 870-877.
50. Gunderson, K.L.; Steemers, F.J.; Lee, G.; Mendoza, L.G.; Chee, M.S. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet., 2005, 37, 549-554.
51. Lieberfarb, M.E.; Lin, M.; Lechpammer, M.; Li, C.; Tanenbaum, D.M.; Febbo, P.G.; Wright, R.L.; Shim, J.; Kantoff, P.W.; Loda, M.; Meyerson, M.; Sellers, W.R. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res., 2003, 63, 4781-4785.
52. Torring, N.; Borre, M.; Sorensen, K.D.; Andersen, C.L.; Wiuf, C.; Orntoft, T.F. Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. Br. J. Cancer., 2007, 96, 499-506.
53. Dutt, A.; Beroukhim, R. Single nucleotide polymorphism array analysis of cancer. Curr. Opin. Oncol., 2007, 19, 43-49.
54. Dumur, C.I.; Dechsukhum, C.; Ware, J.L.; Cofield, S.S.; Best, A.M.; Wilkinson, D.S.; Garrett, C.T.; Ferreira-Gonzalez, A. Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics, 2003, 81, 260-269.
55. Lips, E.H.; Dierssen, J.W.; van Eijk, R.; Oosting, J.; Eilers, P.H.; Tollenaar, R.A.; de Graaf, E.J.; van't Slot, R.; Wijmenga, C.; Morreau, H.; van Wezel, T. Reliable high throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffinembedded tumors using single nucleotide polymorphism arrays. Cancer Res., 2005, 65, 10188-10191.
56. Pollack, J.R.; Perou, C.M.; Alizadeh, A.A.; Eisen, M.B.; Pergamenschikov, A.; Williams, C.F.; Jeffrey, S.S.; Botstein, D.; Brown, P.O. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet., 1999, 23, 41-46.
57. Brookman-Amissah, N.; Duchesnes, C.; Williamson, M.P.; Wang, Q.; Ahmed, A.; Feneley, M.R.; Mackay, A.; Freeman, A.; Fenwick, K.; Iravani, M.; Weber, B.; Ashworth, A.; Masters, J.R. Genomewide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH. Prostate Cancer Prostatic Dis., 2005, 8, 335-343.
58. Wolf, M.; Edgren, H.; Muggerud, A.; Kilpinen, S.; Huusko, P.; Sorlie, T.; Mousses, S.; Kallioniemi, O. NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cell Oncol., 2005, 27, 169-173.
59. Ishkanian, A.S.; Malloff, C.A.; Watson, S.K.; DeLeeuw, R.J.; Chi, B.; Coe, B.P.; Snijders, A.; Albertson, D.G.; Pinkel, D.; Marra, M.A.; Ling, V.; MacAulay, C.; Lam, W.L. A tiling resolution DNA microarray with complete coverage of the human genome. Nat. Genet., 2004, 36, 299-303.
60. Paris, P.L.; Albertson, D.G.; Alers, J.C.; Andaya, A.; Carroll, P.; Fridlyand, J.; Jain, A. N.; Kamkar, S.; Kowbel, D.; Krijtenburg, P.J.; Pinkel, D.; Schroder, F.H.; Vissers, K.J.; Watson, V.J.; Wildhagen, M.F.; Collins, C.; Van Dekken, H. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am. J. Pathol., 2003, 162, 763-770.
61. van Duin, M.; van Marion, R.; Vissers, K.; Watson, J.sE.; van Weerden, W.M.; Schroder, F.H.; Hop, W.C.; van der Kwast, T.H.; Collins, C.; van Dekken, H. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer., 2005, 44, 438-449.
62. Zhou, S.; Kassauei, K.; Cutler, D.J.; Kennedy, G.C.; Sidransky, D.; Maitra, A.; Califano, J. An oligonucleotide microarray for high throughput sequencing of the mitochondrial genome. J. Mol. Diagn., 2006, 8, 476-482.
63. Ge, H. UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Res., 2000, 28, e3.
64. Liotta, L.; Petricoin, E. Molecular profiling of human cancer. Nat. Rev. Genet., 2000, 1, 48-56.
65. MacBeath, G.; Schreiber, S.L. Printing proteins as microarrays for high throughput function determination. Science, 2000, 289, 1760-1763.
66. Paweletz, C.P.; Charboneau, L.; Bichsel, V.E.; Simone, N.L.; Chen, T.; Gillespie, J. W.; Emmert-Buck, M.R.; Roth, M. J.; Petricoin, I.I.I.EF; Liotta, L.A. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 2001, 20, 1981-1989.
67. Zhu, H.; Snyder, M. Protein arrays and microarrays. Curr. Opin. Chem. Biol., 2001, 5, 40-45.
68. Zhu, H.; Snyder, M. Protein chip technology. Curr. Opin. Chem. Biol., 2003, 7, 55-63.
69. Charboneau, L.; Scott, H.; Chen, T.; Winters, M.; Petricoin, E.F.3rd; Liotta, L.A.; Paweletz, C.P. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct. Genomic Proteomic., 2002, 1, 305-315.
70. Lal, S.P.; Christopherson, R.I.; dos Remedios, C.G. Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today., 2002, 7, S143-149.
71. MacBeath, G. Protein microarrays and proteomics. Nat. Genet., 2002, (Suppl 32), 526-532.
72. Cutler, P. Protein arrays: the current state-of-the-art. Proteomics, 2003, 3, 3-18.
73. Grubb, R.L.; Calvert, V.S.; Wulkuhle, J.D.; Paweletz, C.P.; Linehan, W.M.; Phillips, J.L.; Chuaqui, R.; Valasco, A.; Gillespie, J.; Emmert-Buck, M.; Liotta, L.A.; Petricoin, E.F. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics, 2003, 3, 2142-2146.
74. Liotta, L.A.; Espina, V.; Mehta, A.I.; Calvert, V.; Rosenblatt, K.; Geho, D.; Munson, P.J.; Young, L.; Wulfkuhle, J.; Petricoin, E.F.III. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell, 2003, 3, 317-325.
75. Wulfkuhle, J.D.; Aquino, J.A.; Calvert, V.S.; Fishman, D.A.; Coukos, G.; Liotta, L.A.; Petricoin, E.F.III. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics, 2003, 3, 2085-2090.
76. Kodadek, T. Protein microarrays: prospects and problems. Chem. Biol., 2001, 8, 105-115.
77. Stillman, B.A.; Tonkinson, J.L. FAST slides: a novel surface for microarrays. Biotechniques, 2000, 29, 630-635.
78. Tonkinson, J.L.; Stillman, B.A. Nitrocellulose: a tried and true polymer finds utility as a post-genomic substrate. Front Biosci., 2002, 7, c1-12.
79. Espina, V.; Mehta, A.I.; Winters, M.E.; Calvert, V.; Wulfkuhle, J.; Petricoin, E.F.3rd; Liotta, L.A. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics, 2003, 3, 2091-2100.
80. Senior, K. Fingerprinting disease with protein chip arrays. Mol. Med. Today., 1999, 5, 326-327.
81. Lee, Y.; Lee, E.K.; Cho, Y.W.; Matsui, T.; Kang, I.C.; Kim, T.S.; Han, M.H. ProteoChip: a highly sensitive protein microarray prepared by a novel method of protein immobilization for application of protein-protein interaction studies. Proteomics, 2003, 3, 2289-2304.
82. Oh, S.W.; Moon, J.D.; Lim, H.J.; Park, S.Y.; Kim, T.; Park, J.; Han, M.H.; Snyder, M.; Choi, E.Y. Calixarene derivative as a tool for highly sensitive detection and oriented immobilization of proteins in a microarray format through noncovalent molecular interaction. FASEB J., 2005, 19, 1335-1337.
83. Jacobson, J.W.; Oliver, K.G.; Weiss, C.; Kettman, J. Analysis of individual data from bead-based assays ("bead arrays"). Cytometry A, 2006, 69, 384-390.
84. Pelech, S. Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. Curr. Pharm. Biotechnol., 2004, 5, 69-77.
85. Battifora, H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest., 1986, 55, 244-248.
86. Braunschweig, T.; Chung, J.Y.; Hewitt, S.M. Tissue microarrays: bridging the gap between research and the clinic. Expert Rev. Proteomics., 2005, 2, 325-336.
87. Bangur, C.S.; Switzer, A.; Fan, L.; Marton, M.J.; Meyer, M.R.; Wang, T. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene, 2002, 21, 3814-3825.
88. Kononen, J.; Bubendorf, L.; Kallioniemi, A.; Barlund, M.; Schraml, P.; Leighton, S.; Torhorst, J.; Mihatsch, M.J.; Sauter, G.; Kallioniemi, O.P. Tissue microarrays for high throughput molecular profiling of tumor specimens. Nat. Med., 1998, 4, 844-847.
89. Kallioniemi, O.P.; Wagner, U.; Kononen, J.; Sauter, G. Tissue microarray technology for high throughput molecular profiling of cancer. Hum Mol. Genet., 2001, 10, 657-662.
90. Hoos, A.; Cordon-Cardo, C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest., 2001, 81, 1331-1338.
91. Hoos, A.; Urist, M.J.; Stojadinovic, A.; Mastorides, S.; Dudas, M.E.; Leung, D.H.; Kuo, D.; Brennan, M.F.; Lewis, J.J.; Cordon-Cardo, C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Am. J. Pathol., 2001, 158, 1245-1251.
92. Schoenberg Fejzo, M.; Slamon, D.J. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am. J. Pathol., 2001, 159, 1645-1650.
93. Bubendorf, L.; Kolmer, M.; Kononen, J.; Koivisto, P.; Mousses, S.; Chen, Y.; Mahlamaki, E.; Schraml, P.; Moch, H.; Willi, N.; Elkahloun, A.G.; Pretlow, T.G.; Gasser, T. C.; Mihatsch, M.J.; Sauter, G.; Kallioniemi, O.P. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl. Cancer Inst., 1999, 91, 1758-64.
94. Lu, Y.; Cai, Z.; Xiao, G.; Liu, Y.; Keller, E. T.; Yao, Z.; Zhang, J. CCR2 expression correlates with prostate cancer progression. J. Cell Biochem., 2007, 101, 676-685.
95. Fromont, G.; Vallancien, G.; Validire, P.; Levillain, P.; Cussenot, O. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate, 2007, 67, 268-273.
96. Davis, J.N.; Wojno, K.J.; Daignault, S.; Hofer, M.D.; Kuefer, R.; Rubin, M.A.; Day, M.L. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res., 2006, 66, 11897-11906.
97. Aaltomaa, S.; Karja, V.; Lipponen, P.; Isotalo, T.; Kankkunen, J.P.; Talja, M.; Mokka, R. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res., 2006, 26, 4873-4878.
98. Ray, M.E.; Mehra, R.; Sandler, H.M.; Daignault, S.; Shah, R.B. Ecadherin protein expression predicts prostate cancer salvage radiotherapy outcomes. J. Urol., 2006, 176, 1409-1414; discussion 1414.
99. Aaltomaa, S.; Karja, V.; Lipponen, P.; Isotalo, T.; Kankkunen, J.P.; Talja, M.; Mokka, R. Reduced alpha- and beta-catenin expression predicts shortened survival in local prostate cancer. Anticancer Res., 2005, 25, 4707-4712.
100. Abdulkader, I.; Sanchez, L.; Cameselle-Teijeiro, J.; Gude, F.; Chavez, J.E.; Lopez-Lopez, R.; Forteza, J.; Fraga, M. Cell-cycleassociated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol. Rep., 2005, 14, 1527-1531.
101. Prtilo, A.; Leach, F.S.; Markwalder, R.; Kappeler, A.; Burkhard, F.C.; Cecchini, M.G.; Studer, U.E.; Thalmann, G.N. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J. Urol., 2005, 174, 1814-1818; discussion 1818.
102. Li, H.; Zhang, Y.; Glass, A.; Zellweger, T.; Gehan, E.; Bubendorf, L.; Gelmann, E.P.; Nevalainen, M.T. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin. Cancer Res., 2005, 11, 5863-5868.
103. Micke, P.; Kappert, K.; Ohshima, M.; Sundquist, C.; Scheidl, S.; Lindahl, P.; Heldin, C.H.; Botling, J.; Ponten, F.; Ostman, A. In situ identification of genes regulated specifically in fibroblasts of human basal cell carcinoma. J. Invest. Dermatol., 2007, 127, 1516-1523.
104. Zhao, H.; Ramos, C.F.; Brooks, J.D.; Peehl, D.M. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J. Cell Physiol., 2007, 210, 111-221.
105. Morrison, T.B.; Weis, J.J.; Wittwer, C.T. Quantification of lowcopy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques, 1998, 24, 954-958, 960, 962.
106. Untergasser, G.; Koch, H. B.; Menssen, A.; Hermeking, H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res., 2002, 62, 6255-6262.
107. Quayle, S.N.; Hare, H.; Delaney, A.D.; Hirst, M.; Hwang, D.; Schein, J. E.; Jones, S.J.; Marra, M.A.; Sadar, M.D. Novel expressed sequences identified in a model of androgen independent prostate cancer. BMC Genomics, 2007, 8, 32.
108. Wang, S.M. Applying the SAGE technique to study the effects of electromagnetic field on biological systems. Proteomics, 2006, 6, 4765-4768.
109. Orita, M.; Suzuki, Y.; Sekiya, T.; Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 1989, 5, 874-879.
110. Kozlowski, P.; Krzyzosiak, W.J. Combined SSCP/duplex analysis by capillary electrophoresis for more efficient mutation detection. Nucleic Acids Res., 2001, 29, E71.
111. Kourkine, I.V.; Hestekin, C.N.; Magnusdottir, S.O.; Barron, A.E. Optimized sample preparation for tandem capillary electrophoresis single-stranded conformational polymorphism/ heteroduplex analysis. Biotechniques, 2002, 33, 318-320, 322, 324-325.
112. Larsen, L. A.; Johnson, M.; Brown, C.; Christiansen, M.; Frank-Hansen, R.; Vuust, J.; Andersen, P.S. Automated mutation screening using dideoxy fingerprinting and capillary array electrophoresis. Hum. Mutat., 2001, 18, 451-457.
113. Kaneda, R.; Toyota, M.; Yamashita, Y.; Koinuma, K.; Choi, Y.L.; Ota, J.; Kisanuki, H.; Ishikawa, M.; Takada, S.; Shimada, K.; Mano, H. High throughput screening of genome fragments bound to differentially acetylated histones. Genes Cells., 2004, 9, 1167-1174.
114. Miller, A.M.; Lundberg, K.; Ozenci, V.; Banham, A.H.; Hellstrom, M.; Egevad, L.; Pisa, P. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol., 2006, 177, 7398-7405.
115. Lu, Y.; Cai, Z.; Galson, D.L.; Xiao, G.; Liu, Y.; George, D.E.; Melhem, M.F.; Yao, Z.; Zhang, J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate., 2006, 66, 1311-1318.
116. Le, H.; Arnold, J.T.; McFann, K.K.; Blackman, M.R. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am. J. Physiol. Endocrinol. Metab., 2006, 290, E952-E960.
117. Lee, L.J.; Yang, S.T.; Lai, S.; Bai, Y.; Huang, W.C.; Juang, Y.J. Microfluidic enzyme-linked immunosorbent assay technology. Adv. Clin. Chem., 2006, 42, 255-295.
118. Ornstein, D.K.; Petricoin, E.F.III. Proteomics to diagnose human tumors and provide prognostic information Oncology (Williston Park), 2004, 18, 521-529; discussion 529-532.
119. Jackson, D.; Rowlinson, R.A.; Eaton, C.K.; Nickson, J.A.; Wilson, I.D.; Mills, J.D.; Wilkinson, R.W.; Tonge, R.P. Prostatic tissue protein alterations due to delayed time to freezing. Proteomics, 2006, 6, 3901-3908.
120. Wulfkuhle, J.D.; Paweletz, C.P.; Steeg, P.S.; Petricoin, E.F.3rd; Liotta, L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol., 2003, 532, 59-68.
121. Paweletz, C.P.; Ornstein, D.K.; Roth, M.J.; Bichsel, V.E.; Gillespie, J.W.; Calvert, V.S.; Vocke, C.D.; Hewitt, S.M.; Duray, P.H.; Herring, J.; Wang, Q.H.; Hu, N.; Linehan, W.M.; Taylor, P.R.; Liotta, L.A.; Emmert-Buck, M.R.; Petricoin, E.F. III. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res., 2000, 60, 6293-6297.
122. Stoeckli, M.; Chaurand, P.; Hallahan, D.E.; Caprioli, R.M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med., 2001, 7, 493-496.
123. Cazares, L.H.; Adam, B.L.; Ward, M.D.; Nasim, S.; Schellhammer, P.F.; Semmes, O.J.; Wright, G.L.Jr. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin. Cancer Res., 2002, 8, 2541-2552.
124. Chaurand, P.; Caprioli, R.M. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis, 2002, 23, 3125-3135.
125. Petricoin, E.F. 3rd; Ornstein, D.K.; Paweletz, C.P.; Ardekani, A.; Hackett, P.S.; Hitt, B.A.; Velassco, A.; Trucco, C.; Wiegand, L.; Wood, K.; Simone, C.B.; Levine, P.J.; Linehan, W.M.; Emmert-Buck, M.R.; Steinberg, S.M.; Kohn, E.C.; Liotta, L.A. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst., 2002, 94, 1576-1578.
126. Yanagisawa, K.; Shyr, Y.; Xu, B.J.; Massion, P.P.; Larsen, P.H.; White, B.C.; Roberts, J.R.; Edgerton, M.; Gonzalez, A.; Nadaf, S.; Moore, J.H.; Caprioli, R.M.; Carbone, D.P. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet., 2003, 362, 433-439.
127. Cheung, P.K.; Woolcock, B.; Adomat, H.; Sutcliffe, M.; Bainbridge, T.C.; Jones, E.C.; Webber, D.; Kinahan, T.; Sadar, M.; Gleave, M.E.; Vielkind, J. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res., 2004, 64, 5929-5933.
128. Schwartz, S.A.; Weil, R.J.; Johnson, M.D.; Toms, S.A.; Caprioli, R.M. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin. Cancer Res., 2004, 10, 981-987.
129. Tangrea, M.A.; Chuaqui, R.F.; Gillespie, J.W.; Ahram, M.; Gannot, G.; Wallis, B.S.; Best, C.J.; Linehan, W.M.; Liotta, L.A.; Pohida, T.J.; Bonner, R.F.; Emmert-Buck, M.R. Expression microdissection: operator-independent retrieval of cells for molecular profiling. Diagn. Mol. Pathol., 2004, 13, 207-212.
130. Hanson, J.A.; Gillespie, J.W.; Grover, A.; Tangrea, M.A.; Chuaqui, R.F.; Emmert-Buck, M.R.; Tangrea, J.A.; Libutti, S.K.; Linehan, W.M.; Woodson, K.G. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl. Cancer Inst., 2006, 98, 255-261.
131. Grover, A.C.; Tangrea, M.A.; Woodson, K.G.; Wallis, B.S.; Hanson, J.C.; Chuaqui, R. F.; Gillespie, J.W.; Erickson, H.S.; Bonner, R.F.; Pohida, T.J.; Emmert-Buck, M. R.; Libutti, S.K. Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J. Transl. Med., 2006, 4, 13.
132. Englert, C.R.; Baibakov, G.V.; Emmert-Buck, M.R. Layered expression scanning: rapid molecular profiling of tumor samples. Cancer Res., 2000, 60, 1526-1530.
133. Chuaqui, R.F.; Bonner, R.F.; Best, C.J.; Gillespie, J.W.; Flaig, M.J.; Hewitt, S.M.; Phillips, J.L.; Krizman, D.B.; Tangrea, M.A.; Ahram, M.; Linehan, W.M.; Knezevic, V.; Emmert-Buck, M.R. Post-analysis follow-up and validation of microarray experiments. Nat. Genet., 2002, (Suppl 32), 509-514.
134. Tangrea, M.A.; Flaig, M.J.; Ramesh, A.; Best, C.J.; Baibakov, G.V.; Hewitt, S.M.; Mitchell, C.D.; Hartmann, D.P.; Knezevic, V.; Emmert-Buck, M.R.; Chuaqui, R.F. Layered expression scanning: multiplex analysis of RNA and protein gels. Biotechniques, 2003, 35, 1280-1285.
135. Gannot, G.; Tangrea, M.A.; Richardson, A.M.; Flaig, M.J.; Hewitt, S.M.; Marcus, E.M.; Emmert-Buck, M.R.; Chuaqui, R.F. Layered expression scanning: multiplex molecular analysis of diverse life science platforms. Clin. Chim. Acta., 2007, 376, 9-16.
136. Gannot, G.; Tangrea, M.A.; Erickson, H.S.; Pinto, P.A.; Hewitt, S.M.; Chuaqui, R.F.; Gillespie, J.W.; Emmert-Buck, M.R. Layered peptide array for multiplex immunohistochemistry. J. Mol. Diagn., 2007, 9, 297-304.
137. Gannot, G.; Tangrea, M.A.; Gillespie, J.W.; Erickson, H.S.; Wallis, B.S.; Leakan, R.A.; Knezevic, V.; Hartmann, D.P.; Chuaqui, R.F.; Emmert-Buck, M.R. Layered peptide arrays: high throughput antibody screening of clinical samples. J. Mol. Diagn., 2005, 7, 427-436.
138. Morrison, T.; Hurley, J.; Garcia, J.; Yoder, K.; Katz, A.; Roberts, D.; Cho, J.; Kanigan, T.; Ilyin, S.E.; Horowitz, D.; Dixon, J.M.; Brenan, C.J. Nanoliter high throughput quantitative PCR. Nucleic Acids Res., 2006, 34, e123.
139. Brenan, C.J.; Morrison T. High throughput, nanoliter quantitative PCR. Drug Discovery Today: Technologies, 2005, 2, 247-253.
140. Zhang, A.; Pastor, L.; Nguyen, Q.; Luo, Y.; Yang, W.; Flagella, M.; Chavli, R.; Bui, S.; Nguyen, C.T.; Zheng, Z.; He, W.; McMaster, G.; Witney, F. Small interfering RNA and gene expression analysis using a multiplex branched DNA assay without RNA purification. J. Biomol. Screen., 2005, 10, 549-556.
141. Canales, R.D.; Luo, Y.; Willey, J.C.; Austermiller, B.; Barbacioru, C.C.; Boysen, C.; Hunkapiller, K.; Jensen, R.V.; Knight, C.R.; Lee, K.Y.; Ma, Y.; Maqsodi, B.; Papallo, A.; Peters, E.H.; Poulter, K.; Ruppel, P.L.; Samaha, R.R.; Shi, L.; Yang, W.; Zhang, L.; Goodsaid, F.M. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol., 2006, 24, 1115-1122.
142. Yang, W.; Maqsodi, B.; Ma, Y.; Bui, S.; Crawford, K.L.; McMaster, G.K.; Witney, F.; Luo, Y. Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. Biotechniques., 2006, 40, 481-486.